Berobenatide for knee pain in adults with overweight or obesity
Tests berobenatide against placebo in adults with knee osteoarthritis and excess weight.
Plain-language title generated from the registry record
Registry title: A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
Key facts
- Where
- Albuquerque, Charlottesville, Chicago, Clearwater, Colorado Springs, Dallas, Doral, Duncansville, Escondido, Farmington Hills, Fort Worth, Granite Quarry, Gretna, Houston, Jacksonville, Kingwood, Lady Lake, Monroe, Norman, Ocala, Rancho Cucamonga, Salisbury, Shavano Park, Sterling Heights, Stockbridge, Tampa, Tempe, Tomball, Tustin, Waco, Wichita, Wilmington, and Woodstock, United StatesSee the 39 sites
- Phase
- Phase 3
Where in United States
- Albuquerque Clinical Trials, Inc.Albuquerque, United StatesNot yet recruiting
- Charlottesville Medical Research Center, LLCCharlottesville, United StatesNot yet recruiting
- Great Lakes Clinical Trials LLC dba Flourish ResearchChicago, United StatesNot yet recruiting
- Northwestern MedicineChicago, United StatesNot yet recruiting
- Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG)Chicago, United StatesNot yet recruiting
- Northwestern Memorial Hospital, Investigational Drug ServiceChicago, United StatesNot yet recruiting
- Northwestern University Feinberg School of MedicineChicago, United StatesNot yet recruiting
- Clinical Research of West Florida, Inc.Clearwater, United StatesNot yet recruiting
- Skylight Health ResearchColorado Springs, United StatesNot yet recruiting
- Mercy Family ClinicDallas, United StatesNot yet recruiting
- Universal Axon Clinical Research LLCDoral, United StatesTaking people
- Altoona Center For Clinical ResearchDuncansville, United StatesTaking people
- Headlands Research California, LLCEscondido, United StatesNot yet recruiting
- Profound Research, LLCFarmington Hills, United StatesTaking people
- Cedar Health ResearchFort Worth, United StatesNot yet recruiting
- Novant Health Granite Quarry Internal Medicine (knee x-ray)Granite Quarry, United StatesNot yet recruiting
- BRCR Global LouisianaGretna, United StatesNot yet recruiting
- JCCT- Juno NW HoustonHouston, United StatesNot yet recruiting
- Westside Center for Clinical ResearchJacksonville, United StatesNot yet recruiting
- Activian Clinical ResearchKingwood, United StatesNot yet recruiting
- Renstar Medical ResearchLady Lake, United StatesNot yet recruiting
- Monroe Biomedical ResearchMonroe, United StatesTaking people
- AMR ClinicalNorman, United StatesNot yet recruiting
- Renstar Medical ResearchOcala, United StatesNot yet recruiting
- Prospective Research Innovations IncRancho Cucamonga, United StatesNot yet recruiting
- Accellacare - SalisburySalisbury, United StatesNot yet recruiting
- Consano Clinical Research, LLCShavano Park, United StatesNot yet recruiting
- Revive Research Institute, Inc.Sterling Heights, United StatesTaking people
- Clinical Research AtlantaStockbridge, United StatesNot yet recruiting
- Clinical Research of West Florida IncTampa, United StatesNot yet recruiting
- AMR ClinicalTempe, United StatesNot yet recruiting
- DM Clinical ResearchTomball, United StatesNot yet recruiting
- Solace Clinical ResearchTustin, United StatesNot yet recruiting
- Velocity Clinical Research, WacoWaco, United StatesNot yet recruiting
- Elevate Clinical ResearchWichita, United StatesNot yet recruiting
- AccellacareWilmington, United StatesTaking people
- Delaney RadiologistWilmington, United StatesTaking people
- North Georgia Clinical Research, LLCWoodstock, United StatesNot yet recruiting
- North Georgia Internal MedicineWoodstock, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07919678EU 2026-526328-34-00
- Record updated
- 5 November 2026
- Original description
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.Read full original descriptionShow less
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.
Inclusion: Adults 18 years of age or older, or the minimum age of consent according to local regulations; Body mass index of at least 27 kg/m² at Screening; Currently meets American College of Rheumatology (ACR) Criteria for knee OA; Pain due to knee OA; Knee radiograph consistent with knee osteoarthritis and Kellgren-Lawrence Grade 2 or 3; Willingness to complete the required analgesic washout; History of at least 1 self-reported unsuccessful dietary effort to lose body weight.
Exclusion: Self-reported body weight increase or decrease greater than 5% within 90 days before Screening; Prior target-knee replacement, planned target-knee replacement, or planned elective knee surgery during the study; Prior participation in a berobenatide clinical trial with receipt of active treatment or placebo; Known clinically significant gastric-emptying abnormality, history of acute or chronic pancreatitis, or active symptomatic gallbladder disease; Personal history or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2; Significant active or unstable psychiatric disorder; Condition or knee disorder that could confound assessment of target-knee pain; Hypersensitivity to a drug with glucagon-like peptide-1 receptor activity, including berobenatide, or any excipient; History of diabetes or Screening laboratory findings indicative of diabetes; Recent use of weight-loss medication, any glucose-lowering therapy, or other protocol-prohibited treatment.